The United Kingdom and the United States have concluded a major commercial pact that will keep zero import taxes on British medicine products entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase funding on medicines through the public health system. This move secures that tariffs on these vital products will be held at zero for a timeframe of three years.
This agreement comes after earlier warnings to dramatically increase tariffs on branded pharmaceutical imports, with figures mentioned as high as double the cost.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and introduces long-overdue equity to American-British medicine commerce," a release declared.
Economic Importance
Pharmaceuticals are one of the UK's biggest goods shipped to the United States, which is clearly the largest destination for major British pharmaceutical firms.
Export figures show that in the 12 months to the end of September, the UK exported drugs worth £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that span.
"This agreement secures work, stimulates funding and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary stated.
Key NHS Changes
The pact involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must return to the NHS to control costs will be restricted at fifteen percent. Last year, rebates were more than 20%.
Recent Tensions
The pact follows a protracted dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were exacerbated by claims that American consumers were paying several times more for the identical medicines than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward American operations.
The Science Minister stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
